Remnant cholesterol and triglyceride (TG) – but not LDL-C or total cholesterol (TC) – have been linked to intra-pancreatic fat deposition (IPFD) in a general population study of 348 individuals in New Zealand. All participants underwent abdominal MRI and IPFD was quantified. Blood samples were collected in the fasted state for lipid analysis, and linear […]
High TG raises diabetic microvascular complications risk
High triglyceride (TG) levels increase the risk of diabetic microvascular complications, according to results of a retrospective cross-sectional study including 1096 patients with type 2 diabetes (T2DM) and mean TG of 2.22 ±1.52 mmol/L. Multivariate risk assessment showed that patients with T2DM and microvascular complications were at least twice as likely to have elevated TG […]
Sustained TG lowering with volanesorsen in FCS
Recently published data support long-term triglyceride (TG) and pancreatitis reduction with volanesorsen in patients with familial chylomicronaemia syndrome (FCS).
In an open-label extension study of 62 patients who had previously received volanesorsen or placebo in the Phase 3 APPROACH or COMPASS studies, or were treatment-naïve, 46 completed 52 weeks and 21 completed 104 weeks treatment.
Pemafibrate more effective than bezafibrate in hypertriglyceridaemia
The selective PPAR-α agonist, pemafibrate, is more effective at lowering serum triglyceride than the non-selective PPAR-α agonist, bezafibrate, according to results of a randomised crossover study in 60 patients with hypertriglyceridaemia (fasting triglyceride [TG] ≥150 mg/dL) treated by cardiologists in Japan.
Growing evidence supports use of remnant cholesterol in ASCVD risk classification
Including elevated remnant cholesterol in risk assessment for atherosclerotic cardiovascular disease (ASCVD) may better indicate patients who are likely to have a CV event than current models, and help to guide future treatment strategies. Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses growing evidence supporting the use of remnant cholesterol measurement in both primary and secondary prevention settings.
Phase 2 data show promising effects of evinacumab in hypertriglyceridaemia
A Phase 2 trial of evinacumab in patients with severe hypertriglyceridaemia and a history of hospitalisation for acute pancreatitis has not met its primary endpoint, but safety data and changes in lipid and lipoprotein levels support further evaluation in larger trials, conclude the study authors in Nature Medicine.
